Selegiline for Treating Parkinson’s Disease

Peter Riederer, Thomas Müller

Publikation: Kapitel i bog/rapport/konference-proceedingKapitel i bogForskningpeer review

Abstract

Biogenic amine turnover employs the enzymes catechol-O-methyltransferase and monoamine oxidase in neuronal and glial cells. Inhibition of these enzymes elevates biogenic amine levels in the synaptic cleft. Selegiline is a selective, irreversible monoamine oxidase-B inhibitor. Its gastrointestinal absorption is fast, the maximum concentration is reached within 1 h. Main metabolites of selegiline are desmethylselegiline, methamphetamine and L-amphetamine. Symptomatic benefits of selegiline on motor symptoms in patients with Parkinson’s disease are weak. Intervals and severity of off-periods reduce after addition of selegiline, in particular during chronic levodopa intake. Selegiline increases life expectancy in levodopa-treated patients. Selegiline is administered once or twice daily, in 5 mg tablets up to 10 mg, mostly 7.5 mg. Selegiline long-term trials demonstrate, in summary, that combination of selegiline and levodopa may provide a greater clinical benefit and less progression than levodopa alone, even when levodopa without selegiline is taken at substantially higher doses.
OriginalsprogEngelsk
TitelNeuroPsychopharmacotherapy
RedaktørerPeter Riederer, Gerd Laux, Toshiharu Nagatsu, Weidong Le, Christian Riederer
ForlagSpringer
Publikationsdato5. nov. 2022
Sider3149-3157
ISBN (Trykt)9783030620585
ISBN (Elektronisk)9783030620592
DOI
StatusUdgivet - 5. nov. 2022

Citationsformater